A Phase 2 interventional study of SD-101 dermal cream (3%) and SD-101 Dermal Cream (6%) in Epidermolysis Bullosa, sponsored by Scioderm, Inc.. Completed at 7 sites in United States. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2020-01-13.
Sponsored by Scioderm, Inc. (part of BioMarin Pharmaceutical) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Epidermolysis Bullosa with a site in United States — 10 open to participants now, 13 under way, 3 of them phase 3. Epidermolysis Bullosa · United States.
Among the 42 studies in Epidermolysis Bullosa with a site in United States, this one is the 6th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2014, is one of 11 in phase 2, and was the 8th registered.
86 studies on the registry are indexed under Epidermolysis Bullosa; 18 are open to participants now.
Browse Epidermolysis Bullosa studies →10 of the 42 studies in Epidermolysis Bullosa with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 5–21
Paradigm Therapeutics · Sites in United States
Ages 28 days–12 yrs
Xinnate AB · Sites in United States, France, Greece and 4 more countries
Ages 4+
BioMendics, LLC · Sites in United States
Ages 2+
M. Peter Marinkovich · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Epidermolysis Bullosa studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.
This study: 6 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 17 · Phase 3 8
First in 2007; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 15 across 68 interventional studies indexed under Epidermolysis Bullosa.
Median enrollment 16 across the 37 interventional studies, 60 across the 5 observational. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Scioderm, Inc., one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Scioderm, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
BioMarin Pharmaceutical has 5 studies filed under Epidermolysis Bullosa — fewer than ten, so there is no comparison to draw.
6 of the studies in Epidermolysis Bullosa with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482787Phase 3Paradigm TherapeuticsEfficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | 2027-05-17 |
| NCT07027345BioMendics, LLCA Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex | 2027-01 |
| NCT06834035M. Peter MarinkovichTargeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa | 2027-03 |
| NCT07050810Northwestern UniversityThera-Clean® Microbubbles System in Patients With Skin Diseases | 2027-06 |
| NCT06594393Xinnate ABA Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 42 studies in Epidermolysis Bullosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).
This was a Phase 2b, multi-center, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of SD-101 dermal cream (3% or 6%) on skin lesions in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB.
SD-101 cream [containing 3% or 6% or vehicle (0%)] was applied topically, once a day to the entire body for a period of 90 days. Eligible participants had a target wound assessed at baseline. Selected target wound had to be at least a certain age and within a prespecified size range at study entry. Photographic confirmation of the target wound location was collected at baseline, and the picture saved from the first visit was used to confirm location of the target wound at subsequent visits. The participant returned to the study site at Week 2, Month 1, Month 4, and Month 5 (at 14, 30, 60, and 90 days, respectively) to have the target wound previously identified at baseline re-assessed for the level of healing. In addition, changes in itching, pain, body surface area coverage of blisters and lesions, and scaring of the healed target wound were also assessed at each visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SD-101 dermal cream (6%) applied topically once daily over the entire body for 90 days.
Drug: SD-101 Dermal Cream (6%)
SD-101 dermal cream (3%) applied topically once daily over the entire body for 90 days.
Drug: SD-101 dermal cream (3%)
Vehicle dermal cream (SD-101 0%) applied topically once daily over the entire body for 90 days.
Drug: Vehicle (SD-101 0%)
SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
Also known as: SD-101, SD-101-3.0, Zorblisa
SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Also known as: SD-101, SD-101-6.0, Zorblisa
A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.
Also known as: Placebo Comparator, SD-101-0.0
Participants With Documented Complete Closure Of The Target Wound Within 1 Month After Initiation Of Treatment
The ARANZ SilhouetteStar™, a wound imaging, measurement, and documentation system providing accurate wound assessment, was used to measure the target wound at all visits. Information captured included photographic images, quantitative measures, and other target wound assessment data input to the device by the clinician, all obtained with no contact to the participant's skin. Information about the target wound's measurement history was available on this system so that the serial progression of the target wound status could also be calculated and presented.
Time frame: Baseline to 1 Month
Participants With Documented Complete Closure Of The Target Wound Within 2 And 3 Months After Initiation Of Treatment
The ARANZ SilhouetteStar™, a wound imaging, measurement, and documentation system providing accurate wound assessment, was used to measure the target wound at all visits. Information captured included photographic images, quantitative measures, and other target wound assessment data input to the device by the clinician, all obtained with no contact to the participant's skin. Information about the target wound's measurement history was available on this system so that the serial progression of the target wound status could also be calculated and presented.
Time frame: Baseline to Month 2 and Month 3
Percentage Change From Baseline In Lesional Skin Based On Body Surface Area Index (BSAI) Measurements At Month 3
The BSAI is a global measure of disease "spread" with weighting factors. Lesional skin consisted of area(s) that could contain any of the following: blisters, bullae, erosions, ulcerations, scabbing and eschars, as well as areas that are weeping, sloughing, oozing, crusted and denuded. The percentage, ranging from 0% to 100%, of affected body surface area was recorded for each defined body region (head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, and then summed for all body regions to calculate the BSAI. The BSAI affected with blisters and wounds was calculated at baseline and Month 3 to assess the total affected area. Percentage change from baseline was calculated as follows: Percentage change from baseline = 100\*(Post-baseline value minus Baseline value) divided by Baseline value. Mean percentage change from baseline in BSAI is reported. Only participants with data available for analysis at the specified time point are presented.
Time frame: Baseline, Month 3
Participants Experiencing A Change From Baseline In Itching At Day 7
The Itch Man Pruritus Assessment Tool was used to measure the intensity of itching. Itching was assessed and reported at Baseline and Day 7. For participants 6 months to 5 years of age, itching was assessed using the caretaker's response, while in participants 6 years and older, itching was self-reported.
Time frame: Baseline, Day 7
Change From Baseline In Pain At Day 7
Pain was assessed at Baseline and Day 7. The presence and intensity of pain was assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) Pain Scale for participants 6 months to 3 years of age. For participants aged 4 years and older, the Wong Faces Pain Scale was used. Scores were attributed for each of the 5 categories in the FLACC scale from 0 to 2, which resulted in a total score between 0 and 10. The Wong Faces Pain scale used 1 item to rate pain on a 0 to 10 scale. Higher score values indicated more pain.
Time frame: Baseline, Day 7
Participants With Scarring At Week 2, Month 1, Month 2, And Month 3
In the event of a healed wound, where complete closure was confirmed, the extent of scarring was assessed as "Present" or "Absent" at all post-baseline visits (Week 2 and Months 1, 2, and 3).
Time frame: Week 2, Month 1, Month 2, and Month 3
| Milestone | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) |
|---|---|---|---|
| Started | 15 | 16 | 17 |
| Received at least 1 dose of study drug | 15 | 16 | 17 |
| Completed | 12 | 15 | 17 |
| Not completed | 3 | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
The ARANZ SilhouetteStar™, a wound imaging, measurement, and documentation system providing accurate wound assessment, was used to measure the target wound at all visits. Information captured included photographic images, quantitative measures, and other target wound assessment data input to the device by the clinician, all obtained with no contact to the participant's skin. Information about the target wound's measurement history was available on this system so that the serial progression of the target wound status could also be calculated and presented.
| Participants | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) |
|---|---|---|---|
| Yes | 8 | 6 | 7 |
| No | 7 | 10 | 10 |
The ARANZ SilhouetteStar™, a wound imaging, measurement, and documentation system providing accurate wound assessment, was used to measure the target wound at all visits. Information captured included photographic images, quantitative measures, and other target wound assessment data input to the device by the clinician, all obtained with no contact to the participant's skin. Information about the target wound's measurement history was available on this system so that the serial progression of the target wound status could also be calculated and presented.
| Participants | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) |
|---|---|---|---|
| Yes: Month 2 | 9 | 7 | 7 |
| No: Month 2 | 6 | 9 | 10 |
| Yes: Month 3 | 9 | 9 | 9 |
| No: Month 3 | 6 | 7 | 8 |
The BSAI is a global measure of disease "spread" with weighting factors. Lesional skin consisted of area(s) that could contain any of the following: blisters, bullae, erosions, ulcerations, scabbing and eschars, as well as areas that are weeping, sloughing, oozing, crusted and denuded. The percentage, ranging from 0% to 100%, of affected body surface area was recorded for each defined body region (head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, and then summed for all body regions to calculate the BSAI. The BSAI affected with blisters and wounds was calculated at baseline and Month 3 to assess the total affected area. Percentage change from baseline was calculated as follows: Percentage change from baseline = 100\*(Post-baseline value minus Baseline value) divided by Baseline value. Mean percentage change from baseline in BSAI is reported. Only participants with data available for analysis at the specified time point are presented.
| percentage of BSAI | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) |
|---|---|---|---|
| Percentage Change From Baseline In Lesional Skin Based On Body Surface Area Index (BSAI) Measurements At Month 3 | -28.02 ± 35.949 | -42.52 ± 37.624 | -5.75 ± 110.470 |
The Itch Man Pruritus Assessment Tool was used to measure the intensity of itching. Itching was assessed and reported at Baseline and Day 7. For participants 6 months to 5 years of age, itching was assessed using the caretaker's response, while in participants 6 years and older, itching was self-reported.
| Participants | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) |
|---|---|---|---|
| Improved | 5 | 4 | 7 |
| Not Improved | 9 | 12 | 10 |
| Missing | 1 | 0 | 0 |
Pain was assessed at Baseline and Day 7. The presence and intensity of pain was assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) Pain Scale for participants 6 months to 3 years of age. For participants aged 4 years and older, the Wong Faces Pain Scale was used. Scores were attributed for each of the 5 categories in the FLACC scale from 0 to 2, which resulted in a total score between 0 and 10. The Wong Faces Pain scale used 1 item to rate pain on a 0 to 10 scale. Higher score values indicated more pain.
| score on a scale | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) |
|---|---|---|---|
| FLACC Pain Scale | 0.50 ± 0.707 | -0.17 ± 5.307 | -1.60 ± 2.881 |
| Wong Faces Pain Scale | 0.91 ± 2.119 | -0.70 ± 2.908 | 1.08 ± 2.353 |
In the event of a healed wound, where complete closure was confirmed, the extent of scarring was assessed as "Present" or "Absent" at all post-baseline visits (Week 2 and Months 1, 2, and 3).
| Participants | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) |
|---|---|---|---|
| Week 2 — Present | 0 | 0 | 0 |
| Week 2 — Absent | 4 | 1 | 2 |
| Month 1 — Present | 2 | 2 | 2 |
| Month 1 — Absent | 2 | 3 | 3 |
| Month 2 — Present | 0 | 1 | 0 |
| Month 2 — Absent | 1 | 0 | 0 |
| Month 3 — Present | 0 | 0 | 0 |
| Month 3 — Absent | 0 | 2 | 2 |
Collected over From baseline (Day 0) to 30 days after last application of study drug (up to a maximum of 4 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SD-101 Dermal Cream (6%) | 0/15 (0%) | 0/15 (0%) | 9/15 (60%) |
| SD-101 Dermal Cream (3%) | 0/16 (0%) | 2/16 (12.5%) | 13/16 (81.3%) |
| Vehicle (0%) | 0/17 (0%) | 1/17 (5.9%) | 12/17 (70.6%) |
| Event | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) |
|---|---|---|---|
| CellulitisInfections and infestations | 0/15 | 1/16 | 0/17 |
| Wound infectionInfections and infestations | 0/15 | 1/16 | 0/17 |
| Feeding disorderMetabolism and nutrition disorders | 0/15 | 1/16 | 0/17 |
| Bacterial tracheitisInfections and infestations | 0/15 | 0/16 | 1/17 |
| Catheter site cellulitisInfections and infestations | 0/15 | 0/16 | 1/17 |
| PneumoniaInfections and infestations | 0/15 | 0/16 | 1/17 |
| Respiratory disorderRespiratory, thoracic and mediastinal disorders | 0/15 | 0/16 | 1/17 |
| Event | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) |
|---|---|---|---|
| PyrexiaGeneral disorders | 5/15 | 3/16 | 2/17 |
| NasopharyngitisInfections and infestations | 1/15 | 4/16 | 2/17 |
| Application site painGeneral disorders | 2/15 | 3/16 | 1/17 |
| RhinitisInfections and infestations | 2/15 | 0/16 | 0/17 |
| PainGeneral disorders | 2/15 | 0/16 | 0/17 |
| PruritusSkin and subcutaneous tissue disorders | 2/15 | 2/16 | 1/17 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/15 | 0/16 | 1/17 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/15 | 0/16 | 0/17 |
| VomitingGastrointestinal disorders | 2/15 | 1/16 | 1/17 |
| RashSkin and subcutaneous tissue disorders | 1/15 | 0/16 | 2/17 |
Intent-to-treat (ITT) Population: Participants who provided informed consent, had been randomized, and had received at least 1 application of study drug.
| Age, Continuous(years) | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) | Total |
|---|---|---|---|---|
| Mean | 9.55 ± 9.189 | 15.32 ± 15.565 | 11.57 ± 10.358 | 12.19 ± 12.029 |
| Sex: Female, Male(Participants) | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) | Total |
|---|---|---|---|---|
| Female | 9 | 8 | 5 | 22 |
| Male | 6 | 8 | 12 | 26 |
| Ethnicity (NIH/OMB)(Participants) | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 7 | 6 | 17 |
| Not Hispanic or Latino | 11 | 9 | 11 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 1 | 3 |
| White | 11 | 15 | 16 | 42 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Epidermolysis Bullosa Subtype(Participants) | SD-101 Dermal Cream (6%) | SD-101 Dermal Cream (3%) | Vehicle (0%) | Total |
|---|---|---|---|---|
| Simplex | 3 | 4 | 4 | 11 |
| Recessive Dystrophic | 10 | 9 | 10 | 29 |
| Junctional non-Herlitz | 2 | 3 | 3 | 8 |
Ran from Jan 2014 to primary completion in Jun 2014, 5 months.
Results were first posted in Jan 2020, 5 years 6 months after primary completion. A results delay was requested in Oct 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nelitolimod